BioDevelops Pharma

BioDevelops is a specialty pharmaceutical company based in Princeton, New Jersey, focused on developing innovative therapies for rare and orphan diseases. The company's lead candidate, BDV-101, is a controlled-release formulation of diazoxide choline being developed for the treatment of Congenital Hyperinsulinism (HI). BioDevelops leverages the expertise of its leadership team, who have significant experience in the development of KATP channel openers and metabolic treatments. The company aims to address significant unmet medical needs in pediatric and rare disease populations through the optimization of established pharmacological agents. BioDevelops operates as a development-stage entity, advancing its pipeline through clinical milestones.